AGAVE: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews

Overview

Agave (Agave americana) is a plant found in southwestern US and Central and South America. It has thick, rigid leaves that form the shape of a rosette.

Some chemicals in agave might reduce swelling and prevent the growth of some cancer cells. Some chemicals might also cause the uterus to contract.

People use agave for constipation, cancer, male-pattern baldness, diarrhea, and many other conditions, but there is no good scientific evidence to support these uses.

Uses & Effectiveness

We currently have no information for AGAVE overview.

Side Effects

When taken by mouth: There isn't enough reliable information to know if agave is safe or what the side effects might be.

When applied to the skin: Fresh agave is possibly unsafe. Exposure to the fresh agave plant may cause swelling and redness, skin sores, and swelling of small blood vessels within minutes to hours of exposure. The sap appears to be the most irritating part of the plant.

Special Precautions and Warnings

Pregnancy:Taking agave by mouth during pregnancy is likely unsafe. It might stimulate the uterus and cause contractions.

Breast-feeding: There isn't enough reliable information to know if agave is safe to use when breast-feeding. Stay on the safe side and avoid use.

Interactions

We currently have no information for AGAVE overview.

Dosing

There isn't enough reliable information to know what an appropriate dose of agave might be. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult a healthcare professional before using.

View References

REFERENCES:

Backstrand JR, Allen LH, Martinez E, Pelto GH. Maternal consumption of pulque, a traditional central Mexican alcoholic beverage: relationships to infant growth and development. Public Health Nutr 2001;4(4):883-91. View abstract.

Backstrand JR, Goodman AH, Allen LH, Pelto GH. Pulque intake during pregnancy and lactation in rural Mexico: alcohol and child growth from 1 to 57 months. Eur J Clin Nutr 2004;58(12):1626-34. View abstract.

Basilio CM, Seyler L, Bernstein J, et al. Isolation and characterization of an utero-active compound from Agave americana. P R Health Sci J 1989;8(3):295-299. View abstract.

Borup LH, Meehan JJ, Severson JM, et al. Terminal spine of agave plant extracted from patient's spinal cord. AJR Am J Roentgenol 2003;181(4):1155-1156. View abstract.

Brazzelli V, Romano E, Balduzzi A, et al. Acute irritant contact dermatitis from Agave americana L. Contact Dermatitis 1995;33(1):60-61. View abstract.

Brenner S, Landau M, Goldberg I. Contact dermatitis with systemic symptoms from Agave americana. Dermatology 1998;196(4):408-411. View abstract.

Cherpelis BS, Fenske NA. Purpuric irritant contact dermatitis induced by Agave americana. Cutis 2000;66(4):287-8. View abstract.

Crawford GH, Eickhorst KM, McGovern TW. Botanical briefs: the century plant--Agave americana L. Cutis 2003;72(3):188-90. View abstract.

Danielson DR, Reinhard KJ. Human dental microwear caused by calcium oxalate phytoliths in prehistoric diet of the lower Pecos region, Texas. Am J Phys Anthropol 1998;107(3):297-304. View abstract.

Du Toit PJ. Isolation and partial characterization of a protease from Agave americana variegata. Biochim Biophys Acta 1976;429(3):895-911. View abstract.

Golan H, Landau M, Goldberg I, et al. [Dermatitis from contact with Agave americana]. Harefuah 2000;139(7-8):276-8, 326. View abstract.

High WA. Agave contact dermatitis. Am J Contact Dermat 2003;14(4):213-214. View abstract.

Kerner J, Mitchell J, Maibach HI. Irritant contact dermatitis from Agave americana L. Incorrect use of sap as "hair restorer". Arch Dermatol 1973;108(1):102-103. View abstract.

Narro-Robles J, Gutierrez-Avila JH, Lopez-Cervantes M, et al. [Liver cirrhosis mortality in Mexico. II. Excess mortality and pulque consumption]. Salud Publica Mex 1992;34(4):388-405. View abstract.

Peana AT, Moretti MD, Manconi V, et al. Anti-inflammatory activity of aqueous extracts and steroidal sapogenins of Agave americana. Planta Med 1997;63(3):199-202. View abstract.

Ricks MR, Vogel PS, Elston DM, et al. Purpuric agave dermatitis. J Am Acad Dermatol 1999;40(2 Pt 2):356-358. View abstract.

Villarreal R, Martinez O, Berumen U, Jr. Phytobezoar from the stem ("quiote") of the cactus Agave americana: report of case. Am J Gastroenterol 1985;80(11):838-840. View abstract.

Yokosuka A, Mimaki Y, Kuroda M, et al. A new steroidal saponin from the leaves of Agave americana. Planta Med 2000;66(4):393-396. View abstract.

Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., and Schram, K. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem.Behav. 1991;40(3):701-708. View abstract.

Crippa, J. A., Zuardi, A. W., Garrido, G. E., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P. M., Hallak, J. E., McGuire, P. K., and Filho, Busatto G. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 2004;29(2):417-426. View abstract.

Crippa, J. A., Zuardi, A. W., Martin-Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., and Fusar-Poli, P. Cannabis and anxiety: a critical review of the evidence. Hum.Psychopharmacol. 2009;24(7):515-523. View abstract.

Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R., Sanvito, W. L., Lander, N., and Mechoulam, R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980;21(3):175-185. View abstract.

Harvey, D. J., Samara, E., and Mechoulam, R. Comparative metabolism of cannabidiol in dog, rat and man. Pharmacol Biochem.Behav. 1991;40(3):523-532. View abstract.

Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., and Izzo, A. A. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem. 2004;89(1):134-141. View abstract.

Lynch, M. E. and Campbell, F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br.J.Clin.Pharmacol. 2011;72(5):735-744. View abstract.

Massi, P., Vaccani, A., Bianchessi, S., Costa, B., Macchi, P., and Parolaro, D. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol.Life Sci. 2006;63(17):2057-2066. View abstract.

Massi, P., Vaccani, A., Ceruti, S., Colombo, A., Abbracchio, M. P., and Parolaro, D. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp.Ther. 2004;308(3):838-845. View abstract.

Ohlsson, A., Lindgren, J. E., Andersson, S., Agurell, S., Gillespie, H., and Hollister, L. E. Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed.Environ Mass Spectrom. 1986;13(2):77-83. View abstract.

Perras, C. Sativex for the management of multiple sclerosis symptoms. Issues Emerg.Health Technol. 2005;(72):1-4. View abstract.

Richards, B. L., Whittle, S. L., and Buchbinder, R. Neuromodulators for pain management in rheumatoid arthritis. Cochrane.Database.Syst.Rev. 2012;1:CD008921. View abstract.

Rog, D. J., Nurmikko, T. J., and Young, C. A. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther. 2007;29(9):2068-2079. View abstract.

Rog, D. J., Nurmikko, T. J., Friede, T., and Young, C. A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 9-27-2005;65(6):812-819. View abstract.

Srivastava, M. D., Srivastava, B. I., and Brouhard, B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 1998;40(3):179-185. View abstract.

Consroe PF, Wokin AL. Anticonvulsant interaction of cannabidiol and ethosuximide in rats. J Pharm Pharmacol 1977;29(8):500-1. View abstract.

Cortopassi J. Warfarin dose adjustment required after cannabidiol initiation and titration. Am J Health Syst Pharm. 2020;77(22):1846-1851. View abstract.

Couch DG, Cook H, Ortori C, Barrett D, Lund JN, O'Sullivan SE. Palmitoylethanolamide and Cannabidiol Prevent Inflammation-induced Hyperpermeability of the Human Gut In Vitro and In Vivo-A Randomized, Placebo-controlled, Double-blind Controlled Trial. Inflamm Bowel Dis. 2019;25(6):1006-1018. View abstract.

Covington TR, et al. Handbook of Nonprescription Drugs. 11th ed. Washington, DC: American Pharmaceutical Association, 1996.

Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 2011;25(1):121-30. View abstract.

Crippa JAS, Pacheco JC, Zuardi AW, et al. Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Cannabis Cannabinoid Res 2021. View abstract.

Crippa JAS, Zuardi AW, Guimarães FS, et al. Burnout and Distress Prevention With Cannabidiol in Front-line Health Care Workers Dealing With COVID-19 (BONSAI) Trial Investigators. Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic: A Randomized Clinical Trial. JAMA Netw Open. 2021 Aug 2;4(8):e2120603. View abstract.

Crockett J, Critchley D, Tayo B, Berwaerts J, Morrison G. A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects. Epilepsia. 2020;61(2):267-277. View abstract.

Crossland BW, Rigby BR, Duplanty AA, et al. Acute supplementation with cannabidiol does not attenuate inflammation or improve measures of performance following strenuous exercise. Healthcare (Basel) 2022;10(6):1133. View abstract.

Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002;23(5):238-45. View abstract.

Czégény Z, Nagy G, Babinszki B, et al. CBD, a precursor of THC in e-cigarettes. Sci Rep 2021;11(1):8951. View abstract.

Dahlgren MK, Lambros AM, Smith RT, Sagar KA, El-Abboud C, Gruber SA. Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial. Commun Med (Lond) 2022;2(1):139. View abstract.

Dalton WS, Martz R, Lemberger L, et al. Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clin Pharmacol Ther 1976;19(3):300-9. View abstract.

Darweesh RS, Khamis TN, El-Elimat T. The effect of cannabidiol on the pharmacokinetics of carbamazepine in rats. Naunyn Schmiedebergs Arch Pharmacol. 2020. View abstract.

Davis BH, Beasley TM, Amaral M, et al. Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment-Resistant Epilepsy. Clin Pharmacol Ther 2021;110(5):1368-1380. View abstract.

Ayenew KD, Wasihun Y. Hepatoprotective effect of methanol extract of Agave americana leaves on paracetamol induced hepatotoxicity in Wistar albino rats. BMC Complement Med Ther 2023;23(1):99. View abstract.